Dobbs S P, Gribbin C, Chan S Y, Bessell E M
Department of Clinical Oncology, City Hospital, Nottingham, U.K.
Eur J Cancer. 1994;30A(1):30-3. doi: 10.1016/s0959-8049(05)80013-9.
20 patients with ovarian carcinoma whose disease had relapsed (1-42 months, median 4 months) after showing either response or stable disease to carboplatin, were treated with ifosfamide (5 g/m2 intravenously over 24 h, day 1) and carboplatin (200 mg/m2 intravenously day 2) as second-line treatment. The mean number of treatment cycles was 3.5 (range 1-6). The major toxicities were thrombocytopenia (WHO grade 3/4, 25%), neutropenia (WHO grade 3/4, 40%) and encephalopathy (WHO grade 3/4, 15%). Overall response rate was 15% [complete response, 0; partial response, 3 (15%); no change, 5 (25%) and progressive disease, 12 (60%)]. The median survival from the date of second-line treatment was 7 months. This combination offers no advantage over either agent used alone.
20例卵巢癌患者在对卡铂治疗出现缓解或病情稳定后疾病复发（复发时间为1 - 42个月，中位时间4个月），接受异环磷酰胺（第1天，24小时内静脉输注5 g/m²）和卡铂（第2天，静脉输注200 mg/m²）作为二线治疗。治疗周期的平均数为3.5（范围1 - 6）。主要毒性反应为血小板减少（世界卫生组织3/4级，25%）、中性粒细胞减少（世界卫生组织3/4级，40%）和脑病（世界卫生组织3/4级，15%）。总缓解率为15%[完全缓解，0例；部分缓解，3例（15%）；病情无变化，5例（25%）；疾病进展，12例（60%）]。自二线治疗开始的中位生存期为7个月。该联合治疗方案并不比单独使用任何一种药物更具优势。
